Preclinical studies identified a KLH-conjugated survivin peptide mimic SVN53-67/M57-KLH (SurVaxM) that stimulates immune response against murine glioma in vivo and human glioma cells in vitro was used to test safety, immunogenicity and clinical effects in glioma patients in a clinical study [162]. This evidence concerns the gene BIRC5 and glioma.